Protective CD8+ T lymphocytes in Primates Immunized with Malaria Sporozoites by Weiss, Walter R. & Jiang, Chengyong George
Protective CD8+ T lymphocytes in Primates Immunized
with Malaria Sporozoites
Walter R. Weiss*, Chengyong George Jiang
¤
Infectious Disease Department, Naval Medical Research Center, Silver Spring, Maryland, United States of America
Abstract
Live attenuated malaria vaccines are more potent than the recombinant protein, bacterial or viral platform vaccines that
have been tested, and an attenuated sporozoite vaccine against falciparum malaria is being developed for humans. In mice,
attenuated malaria sporozoite vaccines induce CD8
+ T cells that kill parasites developing in the liver. We were curious to
know if CD8
+ T cells were also important in protecting primates against malaria. We immunized 9 rhesus monkeys with
radiation attenuated Plasmodium knowlesi sporozoites, and found that 5 did not develop blood stage infections after
challenge with live sporozoites. We then injected 4 of these protected monkeys with cM-T807, a monoclonal antibody to
the CD8 molecule which depletes T cells. The fifth monkey received equivalent doses of normal IgG. In 3 of the 4 monkeys
receiving cM-T807 circulating CD8
+ T cells were profoundly depleted. When re-challenged with live sporozoites all 3 of these
depleted animals developed blood stage malaria. The fourth monkey receiving cM-T807 retained many circulating CD8
+ T
cells. This monkey, and the vaccinated monkey receiving normal IgG, did not develop blood stage malaria at re-challenge
with live sporozoites. Animals were treated with antimalarial drugs and rested for 4 months. During this interval CD8
+ T cells
re-appeared in the circulation of the depleted monkeys. When all vaccinated animals received a third challenge with live
sporozoites, all 5 monkeys were once again protected and did not develop blood stage malaria infections. These data
indicate that CD8
+ T cells are important effector cells protecting monkeys against malaria sporozoite infection. We believe
that malaria vaccines which induce effector CD8+ T cells in humans will have the best chance of protecting against malaria.
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Introduction
Mice [1,2], monkeys [3], and humans [4] can be protected
against malaria infection by live attenuated malaria sporozoite
vaccines, and a commercial attenuated sporozoite vaccine against
falciparum malaria is being developed [5]. In mice, attenuated
sporozoite vaccines induce CD8
+ T cells which kill parasites
developing in the liver. Two studies have found that mice depleted
of CD8
+ T cells are no longer protected by attenuated sporozoite
vaccines [6,7]. However, a third study using a different mouse/
malaria combination did not confirm this finding, indicating that
other immune effectors might be involved in protecting mice [8].
In primates and humans protected by attenuated sporozoite
vaccines the immune responses which kill developing parasites
have not been identified. In this paper we have protected monkeys
with an attenuated sporozoite vaccine, and show that this
protection disappears when animals are treated with a monoclonal
antibody to CD8 that depletes circulating lymphocytes [9]. In
addition, we find that as the effects of the monoclonal antibody
wane and CD8
+ lymphocytes reappear, monkeys regain the
protective immunity they had lost. Since in both mammalian
models (mice and monkeys) CD8
+ effector cells play a key role in
protection from live attenuated sporozoite vaccines, it is likely that
CD8
+ cells are important immune effector cells against human
malaria as well.
Results
Immunization and 1
st Challenge
A total of 9 rhesus monkeys were immunized with irradiated
Plasmodium knowlesi (Pk) sporozoites in two cohorts of 5 and 4
animals. Each cohort of vaccinated monkeys and 5 naı ¨ve controls
were challenged with infectious Pk sporozoites. All control
monkeys developed blood stage infections after challenge. Two
vaccinated animals in each of the cohorts became infected (data
not shown) but a total of five vaccinated animals were protected, 3
from Cohort 1 and 2 from Cohort 2. (Table 1, monkeys A–E).
In blood taken two weeks after the last vaccination, we could not
detect CD4+ or CD8+ T cells reactive to the Pk Circumsporozoite
Protein (PkCSP) or Pk Apical Merozoite Antigen 21 (PkAMA1)
using assays for Interferon-c (data not shown) [10]. However, all
vaccinated monkeys had strong serum IFAT titers against Pk
sporozoites (data not shown) [11].
Anti-CD8 treatment and 2
nd Challenge Cohort 1
Two months after their 1st Challenge, monkeys B and C were
treated with cM-T807, a humanized mouse Mab to CD8 alpha
chain [9]. Monkey A received control human IgG. After antibody
treatments, monkeys A, B and and C and 3 new controls monkeys
received their 2
nd Challenge with infectious Pk sporozoites.
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Monkey A (receiving human IgG) was protected in the 2
nd
Challenge. Monkey B developed blood stage parasites. The
circulating CD3
+CD8
+ lymphocytes in this animal dropped to
less than 1% of total CD3+ lymphocytes after receiving anti-CD8
Mab. However Monkey C’s circulating CD3
+CD8
+ circulating
lymphocytes only dropped from 39% to 14%, and Monkey C
remained protected. All monkeys with blood stage infections in the
2
nd Challenge (2 vaccinated and 3 controls) had their first parasites
detected in the blood between days 8–12 after challenge. Infected
animals were treated with artesunate and chloroquine and rested
until their 3
rd Challenge.
Anti-CD8 treatment and 2
nd Challenge Cohort 2
Two months after their 1
st Challenge, monkeys D and E were
treated with Mab cM-T807. Both monkeys and 8 new controls
then received their 2
nd Challenge with infectious Pk sporozoites.
All 8 control monkeys developed blood stage infections (Table 1).
Monkeys D and E also were infected in the 2
nd Challenge. The
circulating CD3
+CD8
+ lymphocytes in these animals dropped to
less than 1% of total CD3+ lymphocytes after receiving anti-CD8
Mab. All monkeys had their first parasites detected in the blood
between days 8–12 after challenge. They were treated with
artesunate and chloroquine and rested until their 3
rd Challenge.
3
rd Challenge
Four months after their 2
nd Challenges, the monkeys from
Cohorts 1 and 2 received a 3
rd Challenge with Pk sporozoites.
From Cohort 1 this included 3 vaccinated monkeys A, B and C
and 3 controls from the 2
nd challenge. In Cohort 2, this included 2
vaccinated monkeys D and E and 4 controls from the 2
nd
challenge. At this time, CD3
+CD8
+ circulating lymphocytes had
reappeared (Table 1). All 7 controls developed blood stage
parasites while none of the 5 vaccinated monkeys became infected.
Discussion
In three vaccinated and protected monkeys, Mab treatment
successfully removed circulating CD8
+ lymphocytes, and all three
of these animals lost protection from an attenuated sporozoite
vaccine. As CD8
+ T cells re-appeared in these monkeys, all three
regained protection against malaria infection. In rhesus monkeys,
the CD8 alpha-chain is present at high levels on CD8
+ T cells and
some NK cells, and at low levels on some B cells, CD4
+ CD8
+
double positive T cells and dendritic cells (personal communica-
tion from Louis Picker). While any of these cell types might have
been affected by the anti-CD8 antibody treatments, we think
CD8
+ T cells are most likely involved in killing malaria parasites in
the liver after sporozoite infection. Return of protection after anti-
CD8 Mab treatment might be due to persistent malaria antigen
immunizing the regrown T cells [12]. Alternatively, CD8 Mab
may have blocked function of CD8
+ cells in the liver without
eliminating them, and with time these cells may have regained
their activity.
We were surprised that a larger fraction of vaccinated monkeys
were not protected against malaria infection. In the only previous
paper describing immunization of rhesus monkeys with Pk
sporozoites [3], 3 animals were given a total of 3 million irradiated
parasites IV, and 2/3 were protected when challenged with live
sporozoites. In our 5 monkeys in Cohort 1, we gave a total of 2.8
million sporozoites IV and 3/5 were protected in their 1
st
Challenge. In Cohort 2, we attempted to protect all 4 monkeys by
increasing the immunizing dose to 5.2 million sporozoites.
However in Cohort 2, only 2/4 animals were protected in their
1
st Challenge with live sporozoites. Overall 5/9 vaccinated
monkeys were protected, similar to results in the earlier
publication. This contrasts with the human data on immunization
with P. falciparum sporozoites, where over 90% of human
volunteers have been protected [4].
There are several possible explanations for the poorer efficacy of
the irradiated sporzoite vaccine in monkeys as compared to
humans. Firstly, we gave irradiated Pk sporozoites as they became
available, and our dose size varied considerably which may have
led to less than optimal vaccinations (Table 2 gives the sporozoite
doses for each cohort). Secondly, it is possible that Pk sporozoites
are less immunogenic or more infectious than P. falciparum
sporozoites. Thirdly, human volunteers are immunized and
challenged by the bite of irradiated mosquitoes. In our primate
experiments, we gave sporozoites IV for both immunizations and
challenges. It may be that IV parasites induce different immune
responses from those generated by mosquito bite to the skin [13].
Alternatively, the challenge with live IV sporozoites, bypassing the
skin, may have skipped over an important site of parasite killing
[14].
Table 1. Effect of anti-CD8 Mab treatment in monkeys protected by the irradiated sporozoite vaccine.
Monkey Vaccine
1st Challenge
Infected
% CD8
+
before Ab
Ab before 2nd
Challenge
% CD8
+
after Ab
2nd Challenge
Infected
% CD8
+ before
3rd Challenge
3rd Challenge
Infected
Cohort 1 A Irr.Spz No 29 IgG 37 No 39 No
B Irr.Spz No 38 aCD8 ,1 Yes 24 No
C Irr.Spz No 39 aCD8 14 No 33 No
Controls none 5/5*Yes 3/3* Yes 3/3** Yes
Cohort 2 D Irr.Spz No 30 aCD8 ,1 Yes 15 No
E Irr.Spz No 40 aCD8 ,1 Yes 9 No
Controls none 5/5* Yes 8/8* Yes 4/4** Yes
In the two Cohorts, a total of five monkeys vaccinated with irradiated Pk sporozoites were protected in their 1
st Challenge with malaria sporozoites. Before their 2
nd
Challenge, Monkey A received control IgG while monkeys B–E received anti-CD8 Mab. Monkeys B, D, and E experienced a profound drop in circulating CD3
+CD8
+ T cells
and became infected when given a 2
nd Challenge with sporozoites. Monkey A was protected. Monkey C retained some CD3
+CD8
+ T cells and was also protected. After
the 2
nd Challenge, monkeys B, D, and E and control monkeys were drug treated and rested for 4 months before their 3
rd Challenge. At the time of the 3
rd Challenge
circulating CD3
+CD8
+ T cells had returned, and all 5 vaccinated monkeys were again protected.
*Control monkeys in the 1
st and 2
nd Challenges were malaria naı ¨ve.
**Control monkeys in the 3
rd Challenge had been infected once in the 2
nd Challenge.
doi:10.1371/journal.pone.0031247.t001
CD8+ T Cell in Primates Immunized with Malaria
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31247The genetic diversity of the rhesus monkeys may explain the low
vaccine efficacy. Studies of irradiated sporozoite vaccines in inbred
mice typically use the IV route for immunization and challenge.
Genetically defined mouse strains vary dramatically in the number
of live sporozoites required to infect naı ¨ve animals [15], as well as
the number of irradiated sporozoites required to protect animals
against infection [16,17]. It may be that immunogenetic effects are
more pronounced when sporozoites are given IV, It would be
interesting to vaccinate and challenge monkeys with sporozoites by
mosquito bite, to see if vaccine efficacy was closer to that in
humans.
We were not able to detect T cell responses to two malaria
sporozoite antigens, PkCSP and PkAMA-1, in the venous blood of
our monkeys vaccinated with irradiated sporozoites. In humans,
there is evidence that PfCSP is a protective target antigen. PfCSP
is the basis of the RTS,S vaccine which protects against malaria in
lab and field studies. However, several studies in murine malaria
have indicated that other malaria antigens may be more important
targets of immunity than CSP [18,19,20,21]. Prior to this study,
there was no previously published data on immune responses to
PkCSP in monkeys vaccinated with attenuated sporozoites.
PkAMA1 was first described as a blood stage merozoite antigen,
but AMA1 expression has been found in sporozoites of P.
falciparum [22]. Recent human trials from our laboratory have
shown that human immunized with PfCSP and PfAMA1 can be
protected against infection by sporozoites, while volunteers
immunized with PfCSP alone are not protected (unpublished
data). The choice of PkCSP and PkAMA1 to monitor immune
responses was reasonable, but we do not believe that these antigens
are necessarily the primary targets of the protective immune
responses
In this protocol, we did not test lymphocytes from the livers of
our immunized monkeys for immune responses. In our previous
primate studies using recombinant Pk vaccines, we tested
peripheral blood and readily detected CD4
+ T cell responses to
PkCSP and PkAMA1 but rarely CD8
+ T cell responses [10,23]. In
human volunteers immunized with irradiated sporozoites, T cell
responses are low in peripheral blood [24,25]. Recently, Epstein
et al. [26] have immunized rhesus monkeys with irradiated P.
falciparum sporozoites given IV, and they discovered strong CD4
+
and CD8
+ T cell responses in liver lymphocytes but weaker T cell
responses in circulating lymphocytes. In the same manner, our
vaccinated monkeys may have protective T cells in their liver
compartment while lacking them in the blood.
If CD8+ T cells are important in malaria immunity in monkeys,
these effector cells may well play an important role in protecting
humans against malaria infection. Recombinant vaccines that
induce CD8+ T cell immunity should be vigorously investigated
[27].
Methods
Ethics Statement
We used adult Macaca mulatta (rhesus) monkeys bred in the US
from Indian stock and maintained in a facility accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care (AAALC). The experiments were conducted in
compliance with the Animal Welfare Act and in accordance with
the principles set forth in the ‘‘Guide for the Care and Use of
Laboratory Animals,’’ Institute of Laboratory Animals Resources,
National Research Council, National Academy Press, 1996. All
experiments were approved by the Institutional Animal Care and
Use Committee, Walter Reed Army Institute of Research/Naval
Medical Research Center, Silver Spring Maryland, USA. To
ameliorate suffering, all animals with malaria infections were
closely monitored and treated with anti-malarial drugs.
Malaria sporozoites for challenge and vaccination
Plasmodium knowlesi H strain sporozoites were produced in
Anopheles dirus mosquitoes. Sporozoites were dissected into M199
medium (Sigma-Aldrich Inc., St. Louis, MO) with 5% normal
rhesus monkey serum. For malaria challenge, 100 Pk sporozoites
were injected IV in a 1 ml volume. For malaria vaccination,
sporozoites received 150 Gy from a CS-137 source before being
injected IV in a 1 ml volume.
Experimental Cohorts 1 and 2
These experiments were carried out in two cohorts of monkeys.
Cohort 1 included 5 monkeys for immunization, antibody
treatments, and challenges. After the completion of all work on
Cohort 1, the experiment was repeated in Cohort 2 with 4
monkeys.
Immunization schedules and protection
Cohort 1 included 5 monkeys that received a total of 2.8 million
sporozoites in 10 doses over 24 months. Three of these animals
(Table 1 monkeys A, B, and C) were protected in their 1
st
Challenge with Pk sporozoites and two developed blood stage
infections. Cohort 2 included 4 monkeys that received a total of
5.2 million sporozoites in 6 doses over 12 months. Two of these
monkeys (Table 1 monkeys D and E) were protected in their 1
st
Challenge with Pk sporozoites and two developed blood stage
infections. Table 2 gives the details of sporozoite immunization for
Cohorts 1 and 2.
Monitoring and treatment of malaria infections
After sporozoite challenge, from day 6 to day 30 blood was
obtained by skin prick for thin and thick film malaria slides. After
Giemsa staining, blood was examined under61000 magnification
until 20,000 red cells on thin film were examined. Negative results
were confirmed reading the thick film slides. Protection was
Table 2. Sporozoite immunization schedule.
Dose Month
Irradiated Sporozoites
(thousands)
Cohort 1 1 1 300
24 3 6 6
37 6 7
41 7 2 4
51 8 8 1
62 0 6 6 6
72 2 3 3 3
8 24 1000
Total sporozoites 2837
Cohort 2 1 1 100
22 2 5 0
35 1 7 0
46 5 0 0
59 1 8 0
6 13 4000
Total sporozoites 5200
doi:10.1371/journal.pone.0031247.t002
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Infected animals were treated when parasitemias reached 2% with
artesunate (5 mg/kg single dose) and chloroquine (45 mg/kg in
divided doses over 5 days). Animals were monitored for 30 days to
ensure effectiveness of treatment in clearing malaria infections.
In vivo CD8 depletion
Monkeys were injected with the mouse-human chimeric anti-
human CD8 alpha chain monoclonal antibody, cM-T807 [9]
(Centocor, Inc, Horsham, PA). Monkey A received control
injection with Human IgG (Sigma-Aldrich Inc., St. Louis, MO).
In Cohort 1, 10 mg/kg antibody was injected SC 7 days before
sporozoite challenge, and 5 mg/kg was injected IV 4 days and 1
day before and 2 days after challenge. In Cohort 2, 50 mg/kg
antibody was injected in a single IV dose 3 days before challenge.
Dosing was the same for cM-T807 and control IgG.
Monitoring of blood lymphocyte subsets
Lymphocyte subsets in venous blood samples were determined
using flow cytometry. Reagents were from BD Biosciences (San
Jose, California, USA): anti-CD3apc-cy7, anti-CD4 percp-cy5.5,
anti-CD8PE, anti-CD20 FITC, and anti-CD16 FITC. We used a
LSR-II flow cytometer and DIVA software (BD Biosciences).
Measurement of immune responses after vaccination
Blood lymphocytes were tested by flow cytometry for interferon-
c production when restimulated in vitro using overlapping 15
amino acid peptide sequences from the Pk circumsporozoite
protein and Pk apical merozoite antigen-1 (42 kD) antigens as
previously described [10]. Assessment of serum antibody to Pk
sporozoites was by IFAT [11].
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